Sanofi: positive data for hemophilia in the NEJM
These data demonstrate that efanesoctocog alpha achieves normal or near-normal levels of factor VIII activity (greater than 40%) for the majority of the week on a once-weekly dose", says the healthcare group.
Sanofi points out that its efanesoctocog alpha is currently under accelerated review by the U.S. Food and Drug Administration (FDA), with a decision expected on February 28.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction